Radiopharm Theranostics Ltd (RADX) Cash & Equivalents (2023 - 2025)

Radiopharm Theranostics (RADX) has reported Cash & Equivalents for 3 consecutive years, with $186473.9 the latest figure, recorded in Q2 2025.

• In Q2 2025, Cash & Equivalents rose 52.33% year-over-year to $186473.9; the TTM figure through Jun 2025 stood at $186473.9 (up 52.33% YoY), while the FY2025 annual figure was $29.1 million, up 56.75% from the prior year.
• Cash & Equivalents advanced to $186473.9 in Q2 2025 per RADX's latest filing, from $122414.1 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $11.7 million in Q2 2023 and bottomed at $122414.1 in Q2 2024.
• Historically, Cash & Equivalents has averaged $4.0 million across 3 years, with a median of $186473.9 in 2025.
• Annual changes were most pronounced in 2024 — Cash & Equivalents sank 98.95% — and 2025, when it surged 52.33%.
• Radiopharm Theranostics' Cash & Equivalents stood at $11.7 million in 2023, then plunged by 98.95% to $122414.1 in 2024, then soared by 52.33% to $186473.9 in 2025.
• Business Quant data shows RADX's Cash & Equivalents at $186473.9 in Q2 2025, $122414.1 in Q2 2024, and $11.7 million in Q2 2023.